Singapore's Aslan readies for Taiwan listing, capital raise for cancer pipeline
HONG KONG – With five drugs in its pipeline and a deal with big pharma worth tens of millions of dollars, Singapore drug developer Aslan Pharmaceuticals Pte Ltd. aims to tap the markets in Taiwan, looking to overcome some flagging investor sentiment on biopharma.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST